You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

150 Results
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Daratumumab (subcut) – Daratumumab in combination with Bortezomib, Lenalidomide and Dexamethasone - Newly Diagnosed Transplant Eligible Multiple Myeloma
ODB Limited Use
    lenalidomide - Induction and consolidation therapy for transplant eligible, newly diagnosed multiple myeloma (in combination with daratumumab, bortezomib, and dexamethasone)
ODB - General Benefit
    dexamethasone
ODB Limited Use
    lenalidomide - For the maintenance treatment of patients with newly diagnosed multiple myeloma, following ASCT, who have stable disease or better, with no evidence of disease progression, according to specific criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
daratumumab (subcut),
bortezomib,
lenalidomide,
dexamethasone
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Apr 2026
Drug
Other Name(s): Darzalex® SC
Quick Link(s):
Drug Monograph, Patient Info Sheet
Updated
Apr 2026
Drug
Other Name(s): Darzalex®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Updated
Apr 2026
Regimen
Cancer Type:
Lung
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
ramucirumab (Unfunded),
PACLitaxel,
CARBOplatin
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
New
May 2026
Regimen
Cancer Type:
Lung
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
ramucirumab (Unfunded)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
New
May 2026
Guidelines and Advice
Status: Current
ID: 17-2
Version: 3
Updated
Apr 2026

Pages